Long-term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in the Treatment of Behavioral Symptoms in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017)

Nancy Tich,¹ Anthony Thibodeau,¹ Terri Sebree,¹ Thomas Dobbins,² Stephen O’Quinn¹

¹Zynerba Pharmaceuticals, Devon, PA, USA; ²The Griesser Group, Conshohocken, PA, USA.
Disclosures

• This presentation is intended to communicate scientific and medical information about data from clinical trials involving ZYN002. ZYN002 is an investigational treatment. This means that it is not approved for commercial distribution by government regulatory bodies, including the United States Food and Drug Administration (FDA). This presentation is not designed or intended to promote the use of ZYN002 or any other Company product in order to impact prescribing

• The trials were funded by Zynerba Pharmaceuticals
ZYN2-CL-017 Trial Design and Path of Patient Entry

**CONNECT-FX (ZYN2-CL-016)**
Placebo or ZYN002
250 or 500 mg/day\(^a\)
for 12 weeks
n=230
- Completers, n=197
- Ineligible to continue in trial, n=33

**ZYN2-CL-009**
Open-label ZYN002
250 or 500 mg/day\(^a\)
for 116 weeks
n=10

**Open-label Extension**

ZYN2-CL-017
ZYN002
250 or 500 mg/day\(^a\)
N=240\(^b\)

**Outcomes**

- **Safety**: adverse events, vital signs, laboratory tests, electrocardiograms, and skin assessments
- **Primary efficacy**: change from baseline in Social Avoidance subscale on the ABC-C\(_{FXS}\)

---

\(^a\)Weight-based in 2 divided doses applied twice daily.
\(^b\)Through January 23, 2023.

ABC-C\(_{FXS}\)=Aberrant Behavior Checklist-Community for fragile X syndrome.
Safety Results

• ZYN002 was safe and well tolerated in the ZYN2-CL-017 extension trial in patients with a median duration of exposure of 20 months (range 21 days to 45 months) since trial entry.

• Treatment-emergent adverse events, whether related or unrelated to study drug, were reported by 66.7% of patients; most were related to conditions commonly reported in children and adolescents.

• Treatment-related adverse events were reported in 13.3% of patients; the most common was application site pain (6.7%).
  • Application site pain was transient and reported as mild in 15 and moderate in 1 patient.

• Three patients had increases in ALT of ≥ 3x ULN (2 of the patients had suspected fatty liver disease and 1 patient was receiving valproic acid).

• No clinically significant changes were observed in vital signs or electrocardiograms.
ZYN002 OLE Trial Interim Safety Data – Adverse Events
Most related to conditions commonly reported in children and adolescents

<table>
<thead>
<tr>
<th>Adverse Event Type</th>
<th>Patients (n = 240) or Events, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment Emergent Adverse Events (TEAE)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>66.7%</td>
</tr>
<tr>
<td>Mild-to-moderate TEAEs</td>
<td>97.8% (events)</td>
</tr>
<tr>
<td>TEAEs (≥3% of patients)</td>
<td></td>
</tr>
<tr>
<td>Upper respiratory infection</td>
<td>17.9%</td>
</tr>
<tr>
<td>COVID-19</td>
<td>7.1%</td>
</tr>
<tr>
<td>Application-site pain</td>
<td>6.7%</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>6.3%</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>5.8%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>5.4%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5.0%</td>
</tr>
<tr>
<td>Ear infection</td>
<td>4.6%</td>
</tr>
<tr>
<td>Cough</td>
<td>4.2%</td>
</tr>
<tr>
<td>Influenza</td>
<td>4.2%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>3.8%</td>
</tr>
<tr>
<td>Streptococcal pharyngitis</td>
<td>3.3%</td>
</tr>
<tr>
<td>Discontinuations due to TEAEs</td>
<td>2.9% (7 patients)</td>
</tr>
<tr>
<td>Serious AEs (all non-treatment-related)</td>
<td>11 events in 8 patients</td>
</tr>
<tr>
<td>Treatment-Related TEAEs</td>
<td>13.3%</td>
</tr>
<tr>
<td>Most common treatment-related AE (≥3% of patients)</td>
<td>6.7%</td>
</tr>
</tbody>
</table>

<sup>a</sup>TEAE, whether related or unrelated to study drug.
Sustained Improvement in ABC-C\textsubscript{FXS} Social Avoidance in ZYN002 and Placebo Patients Who Switched to Open-label ZYN002: Patients With Complete Methylation of \textit{FMR1}\textsuperscript{a}

\textsuperscript{a}Patients matching primary efficacy population in RECONNECT.

\textsuperscript{b}Least square mean ± SE; reduction equals improvement.

\textsuperscript{c}ZYN2-CL-016 (CONNECT-FX).
ZYN002-treated Patients Achieved and Maintained Clinically Meaningful Change\textsuperscript{a} in ABC-C\textsubscript{FXS} Social Avoidance: Patients with Complete Methylation of \textit{FMR1}\textsuperscript{b}

\textsuperscript{a}Meaningful change in Social Avoidance: ≥3-point improvement from baseline; maintained for ≥2 consecutive visits.

\textsuperscript{b}Patients matching primary efficacy population in RECONNECT.

\textsuperscript{c}ZYN2-CL-016 (CONNECT-FX).
Conclusions and Ongoing Trial in Fragile X Syndrome

• The interim results from this open-label extension trial support the long-term safety and effectiveness of ZYN002 in children and adolescents with fragile X syndrome, with the greatest improvements seen in those with complete methylation of their FMR1 gene.

• RECONNECT, an ongoing Phase 3, randomized, double-blind, placebo-controlled confirmatory trial evaluating the efficacy and safety of ZYN002 over 18 weeks (NCT04977986) in patients 3 through 22 years of age is actively enrolling.

• For more information on RECONNECT, visit www.fragilexhelp.com.
An Open-label Trial Assessing Short- and Long-term Tolerability and Efficacy of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE)

Helen Heussler,¹ Jonathan Cohen,² Caroline Buchanan,³ Carol O’Neil,⁴ Stephen O’Quinn,⁴ Terri Sebree⁴

¹Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children’s Health Queensland Hospital and Health Services, South Brisbane, Queensland, AU; ²Genetic Clinics Australia, North Caulfield, Victoria, AU; ³Greenwood Genetic Center, Greenville, SC, USA; ⁴Zynerba Pharmaceuticals, Devon, PA, USA.
INSPIRE Phase 2 Trial Design

Assessing the Impact of ZYN002 (Transdermal CBD Gel) on Pediatric Behavioral and Emotional Symptoms of 22q11.2 Deletion Syndrome (NCT05149898, ZYN2-CL-031)

14 Weeks (Period 1)
- 20 patients
- 4 through 17 years of age
- Weight-based dosing:
  - 250 mg to 500 mg daily

ZYN002
- 14 Weeks

24 Weeks (Period 2)
- Open-label extension

Outcomes

• Primary:
  • Safety and tolerability of ZYN002

• Secondary:
  • Efficacy of ZYN002 on anxiety-related and behaviors symptoms
    o Parent Anxiety Rating Scale-Revised (PARS-R)
    o Anxiety, Depression and Mood Scale (ADAMS)
    o Aberrant Behavior Checklist-Community (ABC-C)
## Adverse Events and Safety Over 38 Weeks

<table>
<thead>
<tr>
<th></th>
<th>Patients (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% Patients (n patients or events)</td>
</tr>
<tr>
<td><strong>Treatment-Emergent Adverse Events (TEAEs)(^a)</strong></td>
<td>65% (13 patients; 30 events)</td>
</tr>
<tr>
<td>Mild in severity</td>
<td>86.7%</td>
</tr>
<tr>
<td><strong>Treatment-Related AEs</strong></td>
<td>15% (3 patients; 3 events)</td>
</tr>
<tr>
<td>Application site pain</td>
<td>10% (2 patients; 2 events)</td>
</tr>
<tr>
<td>Application site itching</td>
<td>5% (1 patient; 1 event)</td>
</tr>
<tr>
<td><em>All were mild and transient</em></td>
<td></td>
</tr>
<tr>
<td><strong>Discontinuations due to TEAEs unrelated to ZYN002</strong></td>
<td>1 patient</td>
</tr>
<tr>
<td><strong>Serious AEs</strong></td>
<td>3 (3 patients)</td>
</tr>
<tr>
<td>All unrelated to ZYN002 in Period 2</td>
<td></td>
</tr>
</tbody>
</table>

---

\(^a\)Treatment-emergent adverse events are any events, whether related or unrelated to ZYN002
Significant Improvement in Anxiety as Measured by the PARS-R

Moderate anxiety improved to minimal or mild anxiety

**Period 1**

<table>
<thead>
<tr>
<th>Baseline (n=15)</th>
<th>Week 14 (n=15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.7</td>
<td>8.5</td>
</tr>
</tbody>
</table>

40.6% improvement in anxiety score (P = .0005)

**Period 2**

<table>
<thead>
<tr>
<th>Baseline (n=11)</th>
<th>Week 38 (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.3</td>
<td>7.4</td>
</tr>
</tbody>
</table>

49.4% improvement in anxiety score (P = .0001)

The efficacy analysis for Period 1 included 15 patients for PARS-R (2 patients did not have valid assessments at Week 14).

The efficacy analysis for Period 2 included 11 patients; 1 patient who completed Week 38 stopped drug prior to completion.
Significant Improvements in ADAMS Total Score and All Subscales

Mean Scores and Percentage Improvement

Period 1

ADAMS total and subscale scores

Total Score: 36.1 (P=0.0005) 17.7
General Anxiety: 45.3% (P=0.0005) 10.4 5.1
Depressed Mood: 43.6% (P=0.0033) 7.6 3.4
Social Avoidance: 50.3% (P=0.0084) 8.7 4.3
Obsessive-Compulsive Behavior: 41.3% (P=0.0037) 6.4 0.3
Manic/Hyperactive Behavior: 38.2% (P=0.0032) 7.6 4.4

Period 2

ADAMS total and subscale scores

Total Score: 36.1 (P=0.0064) 15.9
General Anxiety: 56.6% (P=0.0009) 11.5 4.7
Depressed Mood: 55.1% (P=0.0219) 7.8 2.8
Social Avoidance: 64.5% (P=0.0191) 9.6 4.5
Obsessive-Compulsive Behavior: 33.5% (P=0.0124) 8.1 0.7
Manic/Hyperactive Behavior: 54.4% (P=0.0061) 7.6 3.8

The efficacy analysis for Period 1 included 16 patients for ADAMS (1 patient did not have a valid assessment at Week 14).
The efficacy analysis for Period 2 included 11 patients; 1 patient who completed Week 38 stopped drug prior to completion.
Total Score and Obsessive/Compulsive Behavior N=10 as the score for item #16 was missing at Week 38.
The efficacy analysis for Period 1 included 16 patients for ABC-C (1 patient did not have a valid assessment at Week 14).
The efficacy analysis for Period 2 included 11 patients. One patient who completed Week 38 stopped drug prior to completion.
Conclusions

• ZYN002 was well tolerated with a safety profile consistent with other ZYN002 clinical trials

• Statistically significant improvements were reported in anxiety-related and behavioral symptoms:
  • PARS-R
  • Total score and all 5 subscales of ADAMS
  • All 5 subscales of ABC-C

• These findings warrant further study of ZYN002 in children and adolescents with 22q